Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response
Ionizing radiation (IR) therapy is the standard first-line treatment for newly diagnosed patients with glioblastoma (GBM), the most common and malignant primary brain tumor. However, the effects of IR are limited due to the aberrant radioresistance of GBM.
Transcriptome analysis was performed using RNA-seq in radioresistant patient-derived glioma stem-like cells (GSCs). Survival of glioma patient and mice bearing-brain tumors was analyzed by Kaplan–Meier survival analysis. Lipid droplet and γ-H2AX foci-positive cells were evaluated using immunofluorescence staining.
Lipolytic inhibitor G0/G1 switch gene 2 (G0S2) is upregulated in radioresistant GSCs and elevated in clinical GBM. GBM patients with high G0S2 expression had significantly shorter overall survival compared with those with low expression of G0S2. Using genetic approaches targeting G0S2 in glioma cells and GSCs, we found that knockdown of G0S2 promoted lipid droplet turnover, inhibited GSC radioresistance, and extended survival of xenograft tumor mice with or without IR. In contrast, overexpression of G0S2 promoted glioma cell radiation resistance. Mechanistically, high expression of G0S2 reduced lipid droplet turnover and thereby attenuated E3 ligase RNF168-mediated 53BP1 ubiquitination through activated the mechanistic target of rapamycin (mTOR)-ribosomal S6 kinase (S6K) signaling and increased 53BP1 protein stability in response to IR, leading to enhanced DNA repair and glioma radioresistance.
Our findings uncover a new function for lipolytic inhibitor G0S2 as an important regulator for GSC radioresistance, suggesting G0S2 as a potential therapeutic target for treating gliomas.
KeywordsG0/G1 switch gene 2 (G0S2) Glioma stem cell (GSCs) 53BP1 Radioresistance
Aldehyde dehydrogenase 1A3
G0/G1 switch gene 2
Glioma stem-like cell
mammalian target of rapamycin
Neural stem cell
Ribosomal S6 kinase
Glioblastoma (GBM), a WHO grade IV brain tumor is the most common and malignant primary cancer of the central nervous system with a grim median survival of 14.6 months upon diagnosis . Radiotherapy is the standard first line treatment for newly diagnosed patients with gliomas, but its effectiveness is limited given the tumor’s intrinsic resistance and propensity for recurrence [2, 3]. Although possible mechanisms have been attributed to GBM resistance to radiation treatments [4, 5, 6], the molecular mechanisms regulating radiation resistance of GBM are still unclear.
G0/G1 switch gene 2 (G0S2) was initially identified in lymphocytes through pharmaceutical stimulation of the G0 to G1 cell cycle transition [7, 8]. G0S2, a small 12 kDa protein, localizes to the mitochondria [9, 10], endoplasmic reticulum , and lipid droplets within the adipocytes . G0S2 has been shown to play various important roles in cellular functions such as cell proliferation , apoptosis , and oxidative phosphorylation  in humans and mice. G0S2 is demonstrated to function as a lipolytic inhibitor in lipid metabolism to regulate lipid droplet turnover , and lipid droplets were identified as a signature of GBM and inversely correlated with GBM patient survival . Acumulated data have indicated that G0S2 is also involved in cancer [10, 15, 16, 17], including glioma . However, the function of G0S2 in cancers is still largely unknown.
Here, by analyzing gene expression profiles in glioma stem cells (GSCs) treated with fractionated radiation, we found that G0S2 is significantly upregulated in radioresistant GSCs. We firstly examined G0S2 expression in glioma cells and clinical specimens. We then assessed the role of G0S2 in radiation response in glioma stem-like cells (GSCs) and glioma cell lines. Finally, we determined the mechanism by which G0S2 enhances radioresistance in gliomas.
Materials and methods
Glioma U87, LN229, T98G, U251 and LN444 cells were from ATCC (Manassas, VA, USA). Patient-derived glioma stem cell (GSC) lines, GSC 84, GSC 157, GSC 1123 and GSC 83 were from Dr. Ichiro Nakano . GSC cells were maintained in DMEM/F12 supplemented with B27 (1:50), heparin (5 mg/ml), basic FGF (20 ng/ml), and EGF (20 ng/ml), and glioma cells were cultured in 10% FBS/DMEM as we previously described [19, 20].
Antibodies and reagents
The following antibodies were used in this study: an anti-G0S2 (dilution 1:200; Proteintech, IL, USA); an anti-phospho-Histone H2A.X (Ser139) (dilution1:1000; EMD Millipore, Billerica, MA, USA); anti-53BP1 (dilution1:500), anti-RNF168 (dilution1:500), anti-CXCL5 (dilution 1:1000) and anti-Rad51 (dilution 1:1000)(Abcam, Cambridge, MA, USA). The secondary antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Cell culture media and other reagents were from Invitrogen (Carlsbad, CA, USA), Sigma-Aldrich (St. Louis, MO, USA) or Peprotech (Rocky Hill, NJ, USA).
Four fresh samples of human GBM samples and paired normal brain (peritumoral) tissues were obtained from Renji Hospital, Shanghai, China.
G0S2 and RNF168 cDNAs were amplified by RT-PCR from normal human brain tissues and sequenced. The cDNAs were then subcloned into a lentivirus LeGO-iG vector. shRNAs for G0S2 and 53BP1 were purchased from Thermo Fisher Scientific (Waltham, MA, USA). pMT107-His-Ub was described in our previous report .
Cell transfections were performed as we previously described .
RNA-Seq and differentially expressed gene analysis
Total RNA was extracted and purified using the Qiagen RNeasy Mini kit (Valencia, CA, USA) according to the manufacturer’s instructions. The quality of RNA was assessed by bioanalyzer before sequencing. Libraries for poly(A)+ RNA were prepared according to the Illumina protocol. Libraries were sequenced on Illumina HI-SEQ 2500 platforms. The criteria of Differentially Expressed Genes detection in this study are false discovery rate (FDR) < 0.01 and a fold change > 2. Gene Expression Omnibus (GEO) accession code: GSE79772.
Western blotting assay
Western blotting assay was performed as we previously described . Briefly, cells were lysed, and then the lysates were centrifuged. Protein concentrations were determined with a BCA protein assay kit. Equal amounts of cell lysates (a total of 30 μg of protein) were resolved in a 2X SDS lysis buffer and analyzed.
Cell apoptosis assay
Cell apoptosis assay was performed using BD Annexin V: FITC Apoptosis Dectection Kit (BD Biosciences, San Jose, CA, USA), according to the manufacturer’s instructions. Cells (5 × 105) were washed in PBS and centrifuged at 200 x g for 5 min. The supernatant was aspirated. The cell pellet was incubated with annexin-V-FITC (at 1 mg/ml in Hepes buffer with 1.8 mM CaCl2) for 5–10 min at room temperature, and added 1 ml Hepes containing 10 mg/ml propidium iodide. Cells were analysed immediately by flow cytometry.
RNA extraction and quantitative real-time PCR analysis
Total RNA was extracted from indicated cells using Trizol (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions. Quantitative Real-Time PCR was performed in triplicate using the QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, CA, USA) on a Rotorgene 6000 series PCR machine (Corbett Research, Valencia, CA, USA). All mRNA quantification data were normalized to ACTB, which was used as an internal control. The following G0S2 primer sets were used: 5′-GGCCTGATGGAGACTGTGTG-3′ and 5′-CTTGCTTCTGGAGAGCCTGT-3′.
BODIPY 493/503 staining of neutral lipid droplets
GSCs were incubated under normal growth conditions with 100 μM of oleic acid (OA) (Sigma-Aldrich, catalog number: O3008) complexed to albumin at a molar ratio of 8:1for 16 h, and then incubate on BODIPY staining solution in the dark for 15 min at 37 °C according to the manufacturer’s instructions.
Immunofluorescent staining and confocal microscopy
Cells grown on coverslips were permeabilized with 0.3% Triton X-100-PBS for 15 min and blocked with 3% BSA for 60 min. After overnight incubation of primary antibodies at 4 °C, the slides were incubated with Alexa Fluor-labeled secondary antibodies, and then were further stained with Hoechst 33258 for 10 min and evaluated with a LSM710 confocal microscope (Zeiss, Germany).
Athymic (Ncr nu/nu) female mice at an age of 6–8 weeks (SLAC, Shanghai, China) were used. Mice were randomly divided into 5–6 per group. Four thousand GSCs or 1 × 106 human glioma cells were stereotactically implanted into the brain of the animals as we previously described [20, 21]. Mice were euthanized when neuropathological symptoms developed.
Cells or mice were irradiated at indicated doses with an X-RAD 160 irradiation system (Precision X-Ray, Inc., Kentwood, MI, USA). A radiation shield was used to protect animal body.
Colony formation assay
Clonogenic survival assay was performed as previously described [22, 23]. Briefly, approximately 5000 cells after IR were seeded in a 0.5% Noble Agar top layer with a bottom layer of 0.8% Noble Agar in each of the triplicate wells of a 24-well plate. TMZ was added into the top layer. Medium was added after plating and changed every 3 days thereafter. Colonies were scored after 2–4 weeks using Olympus SZX12 stereomicroscope.
Statistical analyses were performed in a GraphPad Prism version 5.0 for Windows (GraphPad Software Inc., San Diego, CA, USA). Survival analysis was carried out by Kaplan-Meier analysis and was compared with the log-rank tests. Comparison of treatments was analyzed using One-way ANOVA with Newman-Keuls post-test or a paired two-way Student’s t test as we previously described . P values less than 0.05 were considered significant.
G0S2 is upregulated in radioresistant glioma stem cells
To identify novel mediators of radiation resistance in GBM, we treated a patient-derived glioma stem cell (GSC) line (GSC 1123-C) with repeated fractionated radiation to establish a radioresistant GSC line (GSC 1123-R). As shown in Additional file 1: Figure S1A, we subjected GSC 1123-C to four rounds of fractionated radiation of 6 Gy every 4 days (total 24 Gy), generating GSCs with greater radiation resistance GSC 1123-R, a pool of cells. GSC 1123-R cells at passage 10 or less were further analyzed. As shown in Additional file 1: Figure S1B and S1C, annexin V staining for apoptotic cells revealed that only 6.1% ± 0.5% of GSC 1123-R cells underwent apoptosis during the 48 h after a single-6 Gy dose irradiation, compared with a 11.2% ± 0.4% of GSC 1123-C cells. Clonogenic assays showed that the surviving fraction of cells receiving single 4- or 6-Gy IR was significantly higher for GSC 1123-R cells than for GSC 1123-C cells (Additional file 1: Figure S1D and S1E). This observation demonstrates that GSC 1123-R cells are more resistant to radiation when compared with GSC 1123-C cells, and were stable in radiation resistance.
We then assessed expression of G0S2 in glioma cells and clinical specimens of patients. We downloaded the GSE67089 dataset  and examined G0S2 mRNA expression in proneural (PN), mesenchymal (MES) subtyped GSCs, astrocytes, 16WF neural stem cells (NSCs) and five established glioma cell lines. As shown in Fig. 1d, G0S2 was expressed at the highest levels in MES GSCs compared with all other cells. G0S2 was also co-expressed with MES-associated genes, CD44 and ALDH1A3 in MES GSCs . The expression level of G0S2 protein was also the highest in MES GSCs, GSC 1123 and GSC 83 (Fig. 1e) when compared to other cell lines that were analyzed. In clinical tumor samples, compared to paired normal brain tissues, G0S2 was found highly expressed in three of four clinical GBM tissue samples (Fig. 1f). To support our findings, we downloaded GSE7696  and GDS1962  datasets and examined expression level of G0S2 mRNA in GBM, low grade (WHO grade II and III) and normal brain tissue controls included in these datasets. As shown in Fig. 1g and h, compared with normal brain tissues and low grade gliomas, the expression level of G0S2 mRNA was significantly elevated in GBM, while no significant differences were measured between normal and low grade gliomas. We also found that the expression level of G0S2 was markedly higher in recurrent GBM than paired newly diagnosed GBM (Fig. 1i).
Last, we examined the relationship of G0S2 expression and glioma patient survival by Kaplan–Meier survival analysis using the GSE13041 dataset . Segregating patients in the GSE13041 dataset by G0S2 expression revealed a statistically significant worse prognosis for GBM patients with high G0S2 (> 1.2 x median level) compared with those with low (< 1.2 x median level) (Fig. 1j). The median patient survival times of these patients were 10.6 and 12.8 months, respectively (p < 0.05). This result supports that G0S2 is upregulated in radiation resistant GSCs and may be involved in glioma progression.
G0S2 mediates lipid droplet turnover and glioma irradiation response
As G0S2 is a lipolytic inhibitor of adipose triglyceride lipase (ATGL) and regulates lipid droplet turnover , we examined whether G0S2-mediated radioresistance is related with G0S2 lipolytic inhibitor activity. GSC 1123 and GSC 83 cells transduced with or without G0S2 shRNAs were incubated in normal medium with oleic acid (OA) for 16 h to promote lipid droplet formation (Fig. 2c). Using BODIPY 493/503, a nonpolar probe selective for neural lipids such as TAG , we identified that lipid droplets in GSC 1123/shG0S2 and GSC 83/shG0S2 cells were significantly smaller and lower numerous compared to those in the control cells, respectively (Fig. 2c and d). We then assessed cell apoptosis using fluorescence activated cell sort (FACS). As shown in Fig. 2e and f, knockdown of G0S2 promoted cell apoptosis in GSC 1123 cells, and IR treatment further increased cell apoptosis, whereas OA pre-treatment inhibited IR-induced cell apoptosis in GSC 1123/shG0S2 cells. These results support that G0S2-enhanced radioresistance is related with G0S2-regulated lipid droplet stability.
We further assessed the effect of G0S2 depletion on tumor growth in the brain of mice in response to IR treatment. Ten days after intracranial implantation of GSCs, half of the mice of each group (GSC 1123/shC or GSC 1123/shG0S2) received local IR to the brain for 4 consecutive days at 2.5 Gy/day. Kaplan-Meier survival assay showed that in mice with GSC 1123/shC tumors but without IR treatments, median survival was 17.0 days post-implantation. In contrast, the animals with shG0S2 tumors survived 21.5 days (p < 0.01) (Fig. 2g). IR treatment had a modest effect on control animal survival, with median survival times of 17.0 and 23.0 days (p < 0.01), respectively. However, the combination of shG0S2 and IR led to the most significant extension of animal survival with a median survival time of 33.0 days when compared to a median survival time of 23.0 days of control mice with IR treatment (p < 0.01) (Fig. 2g). This result suggests that a significant benefit to knockdown of G0S2 and radiation over radiation alone.
G0S2 regulates glioma cell DNA repair in response to IR
G0S2 promotes 53BP1 stability in glioma cells in response to IR
Since 53BP1 stability is regulated by ubiquitination in DNA repair [36, 37], we tested if G0S2 regulates 53BP1 ubiquitination and stability in glioma cells in response to IR. As shown in Fig. 5d, comparing untreated with irradiated glioma cells, 53BP1 unbiquitination was significantly enhanced by IR in control U87 and LN229 cells at 8-h post-IR. However, G0S2 overexpression inhibited IR-stimulated 53BP1 ubiquitination compared with the controls. We subsequently assessed the protein stability of 53BP1 in the presence of cycloheximide (CHX) that blocks de novo protein synthesis with or without G0S2 overexpression in response to IR. As shown in Fig. 5e and f, overexpression of G0S2 markedly inhibited 53BP1 protein degradation compared with the control. Moreover, the treatment with MG132, a proteasome inhibitor, significantly delayed 53BP1 degradation in G0S2-overexpressed cells. This data supports the notion that G0S2 regulates ubiquitination and proteasome-dependent degradation of 53BP1 in gliomas in response to IR.
To further demonstrate that G0S2 regulates glioma radioresistance through 53BP1, we knocked down 53BP1 using shRNAs in U87/G0S2 and LN229/G0S2 cells and determined γ-H2AX expression and γ-H2AX foci formation in response to IR. As shown in Fig. 5g, knockdown of 53BP1 with two different shRNAs, sh53BP1–1 and sh53BP1–2, increased γ-H2AX protein levels in U87/G0S2 and LN229/G0S2 cells compared with the controls in response to IR. Depletion of 53BP1 markedly attenuated γ-H2AX foci cell formation in U87/G0S2 and LN229/G0S2 cells compared with the controls (Fig. 5h and i). Moreover, knockdown of 53BP1 enhanced U87/G0S2 cell radiosensitivity compared with the control (Fig. 5j), and significantly extended animal survival with median survival times of 38.5 days compared to 32.5 days of control animals (Fig. 5k). Taken together, these data support that G0S2 regulates glioma radioresistance through mediating 53BP1 stability in response to IR.
G0S2 activates mTOR-S6K signaling and thereby inhibits RNF168 expression and RNF168-mediated 53BP1 ubiquitination in response to IR
In this study, we described a novel mechanism of radiation resistance in GBM linked to upregulation of G0S2. G0S2 is upregulated in radioresistant GSCs and elevated in clinical GBM biopsies. Modulation of G0S2 expression affects GBM responses to IR treatments in vitro and in vivo through mTOR/S6K/RNF168/53BP1-regulated DNA repair, suggesting G0S2 as a potential mediator of glioma responses to IR. Moreover, G0S2-induced radioresistance is related with G0S2-mediated lipid droplet stability.
Our data demonstrate for the first time that G0S2 functions as a mediator of radiation resistance in gliomas. G0S2 is a 12 kDa small protein that was initially shown to be involved in cell cycle progression [7, 8]. G0S2 was then characterized as an inhibitor of adipose triglyceride lipase (ATGL) to regulate lipolysis . Recently, G0S2 was described as a positive regulator of hypoxia-induced ATP production . G0S2 was rapidly and transiently induced by hypoxia, and physiological enhancement of G0S2 expression prevented cells from ATP depletion and induced a cellular tolerance for hypoxia stress . G0S2 also was identified as a NF-κB-dependent downstream factor of TNF-α in primary foreskin fibroblasts . PN-MES transition of GSCs promoted radioresistance in a TNF-α/NF-kB-dependent manner . Here, we show that G0S2 modulates radiation responses of gliomas. Expression level of G0S2 was upregulated in radioresistant GSCs. Knockdown of G0S2 by shRNAs sensitized glioma cells to IR treatments in vitro and glioma tumorigenicity. In contrast, overexpression of G0S2 increased the resistance of glioma cell and tumor to IR treatments, demonstrating an undescribed function of G0S2 in glioma radioresistance.
Our results suggest that G0S2 mediates glioma radioresistance through 53BP1-regulated DNA repair. Accumulated data demonstrate that 53BP1 is critical in radiation response of tumors [36, 37], including glioma . Depletion of endogenous 53BP1 sensitized glioma cells to IR treatment in vitro and in vivo . Moreover, 53BP1 stability was shown to be regulated by ubiquitination in response to irradiation [31, 37]. Here, our results support this notion and show that G0S2 overexpression inhibited 53BP1 ubiquitination and upregulated 53BP1 foci cell formation in glioma cells, and thereby reduced γ-H2AX expression and γ-H2AX foci cell formation in response to irradiation. Consistent with this, depletion of 53BP1 inhibited G0S2 overexpression-induced radioresistance.
Our results also suggest that G0S2 mediates 53BP1 ubiquitination and stability through mTOR/S6K signaling-regulated RNF168 expression. 53BP1 stability is regulated by E3 ubiquitin ligase RNF168 in DNA damage [37, 38]. mTOR-S6K phosphorylates RNF168 at Ser60 and thereby inhibits its E3 ligase activity, accelerates its proteolysis, and impairs its function in DNA damage response . Additionally, mTOR-S6K signaling is activated by exogenously supplied oleic acid (OA), a monounsaturated omega-9 fatty acid . In this study, we show that lipolytic inhibitor G0S2 reduces lipid droplet turnover and thereby activates mTOR-S6K signaling, inhibits E3 ligase RNF168 expression and RNF168- mediated 53BP1 protein ubiquitination in response to IR. Thus, our data suggest that G0S2 regulates 53BP1 stability and DNA repair through mTOR-S6K signaling-mediated RNF168.
Previous studies have shown G0S2 to be both oncogenic and tumor suppressive. G0S2 was found epigenetically silenced in lung cancer and breast cancer lines , and engineered expression of G0S2 induced cell apoptosis through G0S2 binding to and antagonizing Bcl-2 in a lung and a colon cancer cell line  but not in breast cancer cell lines . In a chronic myeloid leukemia cell line, K562, G0S2 gene was found to be silenced by gene methylation, and upregulation of G0S2 expression by retroviral transduction or treatment with 5-azacytidine inhibited the proliferation of K562 cells both in vitro and in a xenograft model . Although Zagani et al.  demonstrated that Eμ-Myc transgenic mouse model was not the correct model to conduct studies on G0S2, they found deletion of the G0S2 gene in mice did not show any effect on the latency of cancer progression in the Eμ-Myc model of lymphoma . By analyzing The Cancer Genome Atlas (TCGA), Fukunaga et al. showed that pateients in the higher G0S2 expression group had a poorer prognosis . They also demonstrated that G0S2 expression levels were higher in recurrent tumor specimens that that at the initial diagnosis in the same patients . Here in this study, we show that G0S2 promotes tumor growth in gliomas. Compared with paired normal brain tissues, we further found that the level of G0S2 expression was elevated in clinical tumor specimens. Patients with high level of G0S2 expression in GBM have a poorer prognosis compared with those with low level of G0S2 expression. Our analysis of GSE7969 and GDS1962 datasets supports this observation demonstrating that G0S2 expression was increased in GBM tumors compared with normal brain tissues. By using genetic approaches targeting G0S2, we found that shRNA knockdown of G0S2 inhibited glioma tumorigenesis in vivo. Conversely, overexpression of G0S2 promoted tumor growth in orthotopic glioma models. The differences between our results and some of earlier studies of G0S2 in other cancers could reflect context-dependent mechanisms of action in different type of cancers.
That G0S2 functions as an oncogene or tumor suppressor may be related with G0S2 lipolytic inhibitor activity. G0S2 suppressed mouse embryonic fibroblasts (MEF) oncogenic transformation induced by overexpression of HRAS or EGFR, which was independent of G0S2 lipolytic inhibitor function . Lipid droplets were shown to be inversely correlated with GBM patient survival . Depletion of SOAT1, an inhibitor of lipid droplet formation, suppressed GBM growth . In this study, we demonstrate that G0S2-induced radioresistance is related with G0S2-regulated lipid droplet stability in gliomas. Knockdown of G0S2 promoted lipid droplet turnover, cell apoptosis, inhibited radioresistance in GSCs, and extended xenograft tumor animal survival. Consistent with this, oleic acid treatment promoted lipid droplet formation and reduced G0S2 shRNA-inhibited cell apoptosis induced by IR. The molecular insight of relation between lipid droplet turnover and tumorigenicity warrants further inverstigation.
In summary, our results demonstrate a previously unknown function of G0S2 in enhancing glioma radioresistance through regulation of 53BP1 protein stability, which is related with G0S2 lipolytic inhibitor function. The newly elucidated roles of G0S2 in glioma radioresistance also provide a strong rationale for targeting this molecule in clinical treatment of human gliomas.
We thank Ichiro Nakano for providing patient-derived glioma stem cells.
This work was supported in part by National Natural Science Foundation of China (81572467, 81874078 to H. Feng; 81470315, 81772663 to Y. Li; 81502142 to Y. Wang; 81260371 to K. Yang); the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (No. 2014024), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20161310), New Hundred Talent Program (Outstanding Academic Leader) at Shanghai Municipal Health Bureau (2017BR021), and the State Key Laboratory of Oncogenes and Related Genes in China (No. 91–17-25) to H. Feng.
Availability of data and materials
All relevant data and materials are available from the authors. RNA-Seq data reported in this study have been deposited with the Gene Expression Omnibus under the accession GEO ID: GSE79772. All the other data supporting the finding of this study are available within the article and its Supplementary Information files or from the corresponding author on reasonable request.
This study was conceived by HF; HF, YL, and KY designed the study; YW, YH, and WZ performed the experiments; HF, YL, KY, and YW analyzed and interpreted the data; YW. AAA, YB, BH, SC, KY, and YL reviewed the manuscript; HF wrote the paper with comments from all authors.
Ethics approval and consent to participate
All the work related to human tissues were performed under the Institutional Review Board approved protocols approved at Shanghai Jiao Tong University, according to the Declaration of Helsinki, and the investigators obtained informed written consent from the subjects. All animal experiments were performed in accordance to a protocol approved by Shanghai Jiao Tong University Institutional Animal Care and Use Committee (IACUC).
Consent for publication
All authors agree to publish.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 26.Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genet. 2008;1:52.Google Scholar
- 27.Qiu B, Simon MC. BODIPY 493/503 Staining of Neutral Lipid Droplets for Microscopy and Quantification by Flow Cytometry. Bio Protoc. 2016;6:17.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.